Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab-Reference-Cited by-同舟云学术

Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab

Published:2011-09-29 Issue:1 Volume:90 Page:e25-e30
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:

Author:

Carneiro Ângela M.,Costa Raquel,Falcão Manuel S.,Barthelmes Daniel,Mendonça Luis S.,Fonseca Sofia L.,Gonçalves Rita,Gonçalves Conceição,Falcão-Reis Fernando M.,Soares Raquel

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1755-3768.2011.02240.x/fullpdf

Reference48 articles.

1. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration;Ahn;Am J Ophthalmol,2009

2. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients;Alexander;Ophthalmology,2007

3. Pharmacokinetics of intravitreal ranibizumab (Lucentis);Bakri;Ophthalmology,2007a

4. Pharmacokinetics of intravitreal bevacizumab (Avastin);Bakri;Ophthalmology,2007b

5. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study;Bashshur;Am J Ophthalmol,2008

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of ARMS2 (rs10490924), VEGFA (rs3024997), TNFRSF1B (rs1061622), TNFRSF1A (rs4149576), and IL1B1 (rs1143623) Polymorphisms and Serum Levels on Age-Related Macular Degeneration Development and Therapeutic Responses;International Journal of Molecular Sciences;2024-09-09

2. The clinical effects and mechanism of action of ranibizumab in treating myopic choroidal neovascularization;2024-04-26

3. The use of anti-VEGF agents in pregnancy;Eye;2024-03-04

4. Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice;Indian Journal of Ophthalmology;2023-08

5. Reactivation of retinopathy of prematurity after intravitreal bevacizumab monotherapy in aggressive posterior retinopathy of prematurity;Journal of Clinical Ophthalmology and Research;2023